Organon & Co. Stock Plummets to New 52-Week Low of $5.76

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 5.76 on March 23, 2026. This significant decline reflects a challenging year for the company, with its stock price plummeting by 70.59% over the past year, starkly contrasting with the S&P 500's performance, which has seen a gain of 16.12% during the same period. The company's market capitalization stands at USD 1,650 million, and it currently has a price-to-earnings (P/E) ratio of 3.00, indicating a low valuation relative to earnings. Despite a modest dividend yield of 0.94%, Organon has faced difficulties, including a net profit drop of 35.56% in the latest quarter, alongside a negative operating profit trend. Organon's inventory turnover ratio is at its lowest, reflecting potential inefficiencies, while raw material costs have increased by 6.27% year-over-year. The company's return on equity remains at 0.00%, highlighting challenges in generating shareholder value. Overall, the recent price movement underscores the ongoing struggles faced by Organon & Co. in a competitive market landscape.